This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Cramer's 'Mad Money' Recap: Anger Gets You Nowhere

When asked about current market conditions, Ouimet said there are extreme weather events every year and they don't have a sizable impact on the company's profitability. A decline in gasoline prices, however, does make a difference as Mom and Dad are likely to spend a little more at the park if the drive to and from costs a little less.

Ouimet said Cedar Fair is always looking for acquisitions, but noted that great opportunities are harder to find. There have been no new parks built in the past three decades mainly because of the costs involved and the fact that the market has been absorbed by existing parks.

Finally, when asked about the current season, Ouimet mentioned that season ticket sales are up over last year and many of the company's parks are at record levels of ticket sales. He said driving to a local amusement park is far simpler than traveling by air, and that trend won't be changing anytime soon.

Cramer continued his recommendation of Cedar Fair saying the company has a lot more upside to come.

Beyond the Business Section

Sometimes the best investment ideas don't come from the business section, Cramer told viewers. Take Alkermes (ALKS - Get Report), a drug company whose drug Vivitrol is changing the way prescription drug abuse is treated in our country.

Citing a recent article in the New York Times, prescription drug abuse is a problem that needs to "urgently be solved," as some 54% of all overdose deaths are now attributed to painkillers and not traditional illegal narcotics. Enter Vivitrol, a drug that blocks the receptors in the brain that respond to opiates, rendering patients unable to get high. Better still, Vivitrol is only needed once a month.

Cramer said this drug is a huge leap forward from traditional treatments that merely replace dangerous opiates with less dangerous ones and require daily doses. Of the estimated 1.6 million people addicted to opiates, nearly 75% of them will seek treatment eventually, making the market opportunity for Alkermes a sizable one.

While critics cite the high cost of the drug as a major drawback, recent state government reports has found that when considering the total cost of treating an addicted patient, the cost of Vivitrol actually saves money.

2 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
ALKS $63.33 0.62%
DPZ $101.05 0.51%
DNKN $47.50 -0.77%
FUN $56.83 0.02%
MCD $96.96 -0.70%


DOW 17,712.66 +34.43 0.19%
S&P 500 2,061.02 +4.87 0.24%
NASDAQ 4,891.2190 +27.8570 0.57%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs